Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Daré Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform
The intravaginal ring technology platform is designed to deliver targeted and sustained pharmaceutical formulations addressing unmet needs in women’s health SAN DIEGO , April 25, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company
View HTML
Toggle Summary Jessica Grossman, M.D., Joins Daré Bioscience Board of Directors
SAN DIEGO , April 11, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Jessica Grossman , M.D., to its board of directors. Dr. Grossman is currently the CEO of Medicines360, a global nonprofit
View HTML
Toggle Summary Daré Bioscience, Inc. Reports 2017 Financial Results and Provides Business Update
-Conference Call and Webcast Today, April 2 nd , at 4:30 PM Eastern Time - SAN DIEGO , April 02, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced financial results for the full year ended December 31, 2017.
View HTML
Toggle Summary Daré Bioscience, Inc. to Announce Full Year 2017 Financial Results and Host a Live Conference Call and Webcast on Monday, April 2, 2018
SAN DIEGO , March 29, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, announced that it has released financial results for the full year ended December 31, 2017 and will host a live conference call and webcast on Monday, April 2 nd
View HTML
Toggle Summary Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting Injectable Contraceptive
Advancing 6- and 12- month injectable contraceptive development work carried out to date under a subcontract funded by Family Health International (FHI 360) through a grant from the Bill & Melinda Gates Foundation SAN DIEGO , March 12, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience , Inc.
View HTML
Toggle Summary Daré Bioscience, Inc. To Participate in the 30th Annual ROTH Conference
SAN DIEGO, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson , President and Chief Executive Officer, will participate in the 30th Annual ROTH Conference on Monday,
View HTML
Toggle Summary Daré Bioscience, Inc. To Participate in the LD Micro Virtual Conference
SAN DIEGO , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson , President and Chief Executive Officer, will participate in the LD Micro Virtual Conference on Tuesday, March 6,
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Effective License and Collaboration Agreement for Topical Sildenafil for Female Sexual Arousal Disorder
Company fulfills financing requirement under terms of agreement with Strategic Science & Technologies, LLC SAN DIEGO , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it has met the funding requirement
View HTML
Toggle Summary Daré Bioscience, Inc. to raise approximately $10.25 million
SAN DIEGO , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE) today announced the pricing of its previously announced underwritten public offering of 5.0 million shares of its common stock and warrants to purchase up to 3.5 million shares of its common stock.  Each share of
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock
SAN DIEGO , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it intends to offer primary shares of its common stock and warrants to purchase shares of its common stock in a public offering.  The offering
View HTML